- Home
- EQBK vs TYRA Comparison
EQBK vs TYRA Comparison
Compare EQBK & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- TYRA
- Stock Information
- Founded
- EQBK 2002
- TYRA 2018
- Country
- EQBK United States
- TYRA United States
- Employees
- EQBK N/A
- TYRA N/A
- Industry
- EQBK Major Banks
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- EQBK Finance
- TYRA Health Care
- Exchange
- EQBK Nasdaq
- TYRA Nasdaq
- Market Cap
- EQBK 673.9M
- TYRA 576.6M
- IPO Year
- EQBK 2015
- TYRA 2021
- Fundamental
- Price
- EQBK $38.86
- TYRA $9.22
- Analyst Decision
- EQBK Hold
- TYRA Strong Buy
- Analyst Count
- EQBK 6
- TYRA 7
- Target Price
- EQBK $44.20
- TYRA $30.86
- AVG Volume (30 Days)
- EQBK 43.1K
- TYRA 298.0K
- Earning Date
- EQBK 07-15-2025
- TYRA 05-08-2025
- Dividend Yield
- EQBK 1.54%
- TYRA N/A
- EPS Growth
- EQBK 543.37
- TYRA N/A
- EPS
- EQBK 3.93
- TYRA N/A
- Revenue
- EQBK $224,743,000.00
- TYRA N/A
- Revenue This Year
- EQBK $20.11
- TYRA N/A
- Revenue Next Year
- EQBK $10.81
- TYRA N/A
- P/E Ratio
- EQBK $9.90
- TYRA N/A
- Revenue Growth
- EQBK 56.39
- TYRA N/A
- 52 Week Low
- EQBK $32.24
- TYRA $6.42
- 52 Week High
- EQBK $50.85
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- EQBK 46.14
- TYRA 41.08
- Support Level
- EQBK $38.59
- TYRA $8.75
- Resistance Level
- EQBK $39.49
- TYRA $9.68
- Average True Range (ATR)
- EQBK 0.68
- TYRA 0.67
- MACD
- EQBK -0.21
- TYRA -0.12
- Stochastic Oscillator
- EQBK 17.26
- TYRA 5.96
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.